Making Genomically-Informed Treatment Management Decisions-Making Genomically-Informed Treatment Management Decisions

Video Transcription

Video Summary

The webinar featured Dr. Devyani Chakravarti discussing precision oncology and how tumor sequencing helps guide cancer treatment decisions. She explained the five-step workflow: diagnosis, tumor and normal sample sequencing, bioinformatic analysis, molecular pathology sign-out, and treatment planning. A major focus was distinguishing between driver and passenger mutations and determining whether a genomic alteration is clinically actionable.<br /><br />Dr. Chakravarti described how evidence levels vary by biomarker and tumor type, using examples such as BRAF V600E, KRAS G12C, and MSI-high status. She emphasized that the same mutation can have different treatment implications depending on the cancer type and allele-specific biology.<br /><br />She then introduced OncoKB, a precision oncology knowledge base that organizes variant interpretation by gene, alteration, tumor type, and level of evidence. OncoKB helps clinicians and pathologists quickly identify standard-of-care options, investigational therapies, and clinical trial opportunities. She noted that the database is governed by expert committees, integrates into molecular pathology workflows, and is free for academic users.<br /><br />Future OncoKB plans include expanding germline variant annotation and improving clinical trial matching.

Keywords

precision oncology

tumor sequencing

clinically actionable mutations

OncoKB

BRAF V600E

KRAS G12C

MSI-high

molecular pathology

clinical trial matching